

DXRX – The Diagnostic Network[®]

Placing the laboratory at the centre
of a Precision Medicine Network



DXRX

The Diagnostic Network[®]

by

Diaceutics

Better Testing, Better Treatment

Discover DXRX – The Diagnostic Network®

Imagine a vibrant marketplace where all stakeholders in Precision Medicine come to find trusted partners and collaborations in a secure, standardized way

With access to a pipeline of global diagnostic testing data on one secure platform

DXRX is an end-to-end solution for the development and commercialization of precision medicine diagnostics., from biomarker discovery to in-market test availability

Learn how the DXRX Network can enable your teams to:

- Profile your organization on a **secure platform** to find the **right commercial opportunities**, without the busy work
- **Be the first to know about biomarker launches** to reduce delays in adopting new tests
- Access **hands on support to improve quality standards** for your specific biomarker testing
- **Reduce overhead costs** by **streamlining** your testing **practices and methodologies**

What's inside

Our Expertise.....	1
The Potential of Precision Medicine.....	2
Solving An Industry Challenge.....	4
Discover the Network.....	7
Features and Benefits.....	10
Solutions and Services.....	14
DXRX Marketplace.....	15
Global Implementation Services.....	19
DXRX Data.....	27
Learn More.....	31

Our Expertise


Our mission is to get every patient the treatment they deserve

- Diaceutics is a data analytics and end-to-end services provider
- We are enabled by DXRX – the world's first Diagnostic Network solution for the development and commercialization of Precision Medicine diagnostics
- We have worked on every Precision Medicine brought to market
- We are trusted by 36 of the world's leading pharma companies

We understand the real-world challenges faced by labs every day




The Growing Challenge And Potential Of Precision Medicine




40% of all FDA approvals in 2018 were for Precision Medicines with 1000 potential therapies in late phase of development

Up to 50%


of eligible patients don't get access to a Precision Medicine due to testing hurdles



It takes up to **4.5 years** for a biomarker test to be developed




It takes up to **3 years for over 70% of labs** to get ready to offer a new biomarker test




The Growing Challenge And Potential Of Precision Medicine

Precision Medicine asset approvals over time (cumulative) in the US by the end of 2018



Solving An Industry Challenge

The 6 Barriers to Diagnostic Adoption Causing Patients to Be Missed




Solving an Industry Challenge

Case study: NSCLC testing and treatment landscape

Testing, Treatment and Data Analysis are all advancing in Non-Small-Cell Lung Cancer. [The Diagnostics 2020 Precision Medicine Report](#) analyses real-world hurdles in the NSCLC diagnostic landscape and explores an industry-wide solution to address an ecosystem which is under-delivering for patients.



~**80%** of PM educational investment by pharma is spent on the predictive biomarker phase



Up to **50%** of eligible patients don't get access to a Precision Medicine due to hurdles in the ecosystem



Today, Lab-developed tests comprise between **40% - 70%** of NSCLC testing



Up to **30%** of the value of a PM treatment is delivered by the diagnostic test



Today it can take up to **4.5 years** for a biomarker to reach an 80% testing rate among patients



The NSCLC testing market is predicted to grow in value from **\$5.3 to \$7.4bn** by 2025



“

“Given the richness of the data we have, Diaceutics has been uniquely positioned to identify that, as an industry, we have been getting it wrong when it comes to patient testing for precision medicines.

We believe that DXRX is the solution.”


Derek Hosty,
Head of Innovation,
Diaceutics

DXRX - The Diagnostic Network[®]

Leverage the **world's first diagnostic network** for Precision Medicine

The world's largest global flow of diagnostic testing data integrating **2500+** laboratories into one secure network

Industry experience from working on every precision medicine brought to market



Recent Network Partnerships




Quality in Control



UK NEQAS



Canadian Pathology Quality Assurance



Collaborate with a global panel of industry KOLs in Precision Medicine diagnostics



Dr Anthony Magliocco,
CEO,
Protean BioDiagnostics Inc.,
US



Markus Eckstein,
MD,
University Hospital Erlangen,
Germany



Kenneth J. Bloom,
CMO,
Invicro and Ambry
Genetics,
US




Keith Kerr,
Professor and Consultant
Pathologist,
Aberdeen University School
of Medicine,
Scotland



Dr Fotios Loupakis,
Medical Oncologist,
Institute of Oncology at Veneto,
Italy

Features and Benefits





Profile your lab on a secure platform to find the right commercial opportunities, without the busy work

Access diagnostic partnering opportunities in a vibrant marketplace where labs, pharma and diagnostic companies come to collaborate on biomarker launches in a standardized way

Showcase your testing capabilities to qualify for collaboration opportunities and celebrate patient testing milestones along the way

Be the first to know about biomarker launches to reduce delays in adopting new tests

Get early visibility of CDx development programs so that you can prevent delays in new biomarker test adoption by preparing your lab through access to training services and emerging technologies





Reduce overhead costs by streamlining your testing practices and methodologies

A close-up, circular frame image of a microscope's eyepieces, symbolizing research and innovation. The image is cropped into a rounded rectangle, showing the two black eyepieces of a microscope in sharp focus. The background is blurred, showing a white laboratory bench and other equipment, emphasizing the scientific nature of the work.



Access hands on support to improve quality standards for your specific biomarker testing needs

Interact with pharmaceutical companies earlier in the development phase to enhance the value delivered by your test throughout commercialization

Maintain a best-in-class workforce through access to industry leading training you need from trusted partners

Respond to and engage with RFPs which are aligned with your organization's capabilities using a standardized partner selection process




Solutions and Services



Discover DXRX Marketplace

DXRX enables a vibrant marketplace where all stakeholders in Precision Medicine come to find trusted partners for collaboration on precision medicine diagnostics in a secure, standardized way





“

“I am honored to be part of what is very much an unprecedented approach to bringing stakeholders on to one secure platform to collaborate around diagnostic testing.



I see there being a huge appetite for this technology not only with pharma, labs and diagnostic companies but also with clinicians and any service provider involved in the process of getting patients treated.”

Kenneth J. Bloom,
CMO, Invicro and Ambry Genetics,
DXRX Network Advisor,
US

Marketplace Collaborations

A DXRX collaboration is an opportunity for multiple stakeholders to work together to solve real-world testing challenges ensuring every patient gets the treatment they deserve

- Profile your lab on a secure platform to find the right commercial opportunities, without the busy work
- Benchmark your testing capabilities and track the real-world impact you are having for patients
- Be the first to know about biomarker launches to reduce delays in adopting new tests



Discover live DXRX collaborations [here](#)




“

“The era of launching a therapy with a single companion diagnostic partner is behind us. We need to consider the global needs of our patients and the regional restrictions commonly faced. This calls for pharma to think beyond a one-size-fits-all approach and embrace the democratisation of testing.”

Peter Keeling,
Chief Executive Officer,
Diaceutics

Global Implementation Services

DXRX is a global implementation network designed to solve real-world testing challenges at local level



Global Implementation Services

DXRX is a global implementation network designed to solve real-world testing challenges at local level

Implementation services are currently available in 51 countries



Test Standardization

Out of the box control materials provided to labs to reduce the time, hassle and cost associated with the adoption of a biomarker test. Enabled by the industry's leading providers in global test standardization.

- Everything the lab requires to prepare earlier for a new biomarker test coming to market
- Delivery of hands on standardization support from DXRX Network experts
- Ensures standardized approach to testing regardless of test modality selected by lab
- Reduces the lag time from drug launch to in market availability of standardized testing

"Since 2005, Targos is vigorously pursuing a high level of international standardization for biomarker analysis. An important part of this has become the Targos Advance Expert Training program, which has been performed for more than 4,000 pathologists. We are excited to join Diaceutics in its effort to realize the full potential of precision medicine through standardization and training."

Gudrun Baenfer,
Head of Advance Training & Consulting Division,
Targos Molecular Pathology





"EMQN CIC and Diaceutics have a shared vision on improving the quality and accuracy of testing to ensure all patients get access, where possible, to the most effective treatments. We are delighted to be offering our ISO 17043 accredited Oncogene panel testing EQA scheme through the DXRX platform to support these goals."

Simon Patton, Managing Director, EMQN CIC

Test Quality Assessment

Accredited EQA training and assessment for labs to maintain superior testing quality at critical stages throughout test development and commercialization. Enabled by industry leading EQA providers globally.

- Standardized quality approach in labs across multiple markets
- Enables provision of EQA/PT services in advance of new biomarker launches
- Hands on support for labs as they are validating/verifying a new assay

Laboratory Tech Support

Hands on troubleshooting and technical support designed to solve specific testing challenges in labs performing biomarker testing

- Provide enhanced support mechanisms to the laboratories performing biomarker testing for your therapy brands
- Technical support for laboratories as they are validating/verifying a new assay
- Technical support for labs not covered by your chosen diagnostic partner



Test Report Optimization

In-lab support provided by DXRX Network experts to optimize biomarker test reporting informing appropriate therapeutic decisions by physicians

- Enable physicians to better understand the results provided in a biomarker test report such as NGS test report
- Ensure physicians are informed on biomarker to therapy linkage
- Provide education and awareness of testing through test report optimization



Test Access and Reimbursement

A mechanism to support biomarker testing access through pharma sponsored reimbursement programmes

- Provide financial support to labs to enable the provision of biomarker testing for your therapy
- Access best-in-class analytics on tests being provided by your labs
- Leverage a secure digital platform for the ordinary reporting of testing



Laboratory Training

In-lab training and coaching services tailored to specific biomarker testing needs. Implemented by DXRX Network pathology experts in 51 countries globally

- Troubleshooting and training provided according to the support needs of the lab
- Enables labs to maintain a best-in-class workforce through CPD and support services
- Delivered by DXRX Network accredited training providers



Educational Resources

Educational content created by domain experts tailored to labs and pathologists providing the information needed to maintain quality testing

- Content created and delivered by lab professionals for lab professionals
- Resources delivered digitally or in-lab as required for your labs
- Leverage robust experience in pharma compliance to inform laboratory education





“

“The precision medicine market is growing rapidly. Approximately 1,000 precision medicine drugs are currently in development and our research shows that by next year, the FDA will be approving more personalized oncology drugs than one-size-fits-all treatments.


“As they shift towards a personalized approach to treating patients, pharmaceutical companies must ensure that they are employing the correct solutions and services to reach every patient eligible for their treatments. Greater transparency and standardization of real-world testing practices on a global scale are key enablers in that testing and treatment journey. “

Karina Hjort,
Senior Director, Innovation,
Diaceutics

Discover the Data

DXRX integrates a global flow of diagnostic testing data into one secure platform

The network has been purpose built to provide unrivalled access to rich data analytics for all stakeholders in precision medicine



DXRX Data

DXRX provides access to the worlds largest diagnostic testing data repository combining multiple sources of information to build a complete picture of a patient's diagnostic journey.

Our lab-derived data is enhanced with diagnostic, claims, registry and demographic data. Every diagnostic event within the data repository has been labelled by our team of clinical experts, this is particularly required for the lab data which is inherently lacking standardization.

Expert data labeling allows for seamless integration across datasets and enables Diaceutics to use innovative algorithms to derive insights.



365 million
de-identified patient records



2500+
Laboratories globally



35
countries



Average 4.3 years'
longitudinal history



670,000
referring physicians



9,500
payors globally



47
disease diagnostic
pathways mapped (DDP)



Data available from
2011

Data Protection, Security and Compliance

Data protection is extremely important to Diaceutics and we always aim to provide clear and transparent information about how its use Personal Data.

Diaceutics' aim is not to be intrusive, but to provide genuine collaboration opportunities for all stakeholders to work together to solve real-world testing challenges, ensuring every patient gets the treatment they deserve. Diaceutics have robust measures and procedures in place to minimize the risk of unauthorized access to the DXRX Platform and to keep it secure.



DXRX is hosted on secure and scalable AWS (Amazon Web Services) infrastructure.

It has been security tested by third party cyber security experts to ensure best practices are adopted and known vulnerabilities are addressed.

DXRX has been privacy assessed by our Legal team to ensure compliance with applicable laws and regulations on data privacy and security.



“

"Our Experts have worked on every precision medicine brought to market which places Diaceutics in a unique position to guide innovative pharmaceutical companies in the integration of best in class precision medicine diagnostics into their business model.

We combine global expertise and local insight to help our partners turn bold vision into long term value."

Susanne Munksted,
Chief Precision Officer,
Diaceutics

Learn More

Talk to us about your diagnostic development and commercialization needs now at marketing@diaceutics.com

